108 results
Page 4 of 6
8-K
EX-1.1
9jjm4nrfn ry0vqmvlx
18 Mar 20
Entry into a Material Definitive Agreement
4:43pm
424B5
mb6nf
18 Mar 20
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.1
b6ed19
2 Mar 20
Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights
7:13am
S-8
EX-5.1
1d2fqcb9o 8ub
2 Mar 20
Registration of securities for employees
12:00am
S-8
kojuk3frpuqw thw
2 Mar 20
Registration of securities for employees
12:00am
8-K
EX-1.1
odmfw0 j507ma8egs
27 Nov 19
Entry into a Material Definitive Agreement
8:40am
424B5
39b8xa tz357f2sdy
27 Nov 19
Prospectus supplement for primary offering
8:38am
8-K
EX-99.1
nw05vqd7
5 Nov 19
Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update
7:00am
8-K
EX-99.1
pyi4tihhyz7l
6 Aug 19
Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
7:01am
8-K
EX-1.1
e5hos06
14 Jun 19
Submission of Matters to a Vote of Security Holders
4:08pm
424B5
920 1xo5up2gi
14 Jun 19
Prospectus supplement for primary offering
4:06pm
424B5
dmrlyrkgpehllq2330vh
12 Jun 19
Prospectus supplement for primary offering
5:13pm
8-K
EX-99.1
w4jcdr
2 May 19
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update
7:03am